UK Clinical Research Network recruits medical technology industry lead:
This article was originally published in Clinica
Executive Summary
The UK medical device industry's part in the government's plans to modernise clinical research will hinge on "the development of a clinical studies portfolio between the public and private sectors", according to an advertisement to recruit the industry lead for the UK Clinical Research Network. The UKCRN will focus initially on six priority healthcare areas, including: cancer, diabetes, neurodegenerative diseases and stroke. Ultimately, the research infrastructure should encompass all major disease categories, says the University of Leeds, for the UKCRN Coordinating Centre, which comprises a consortium of two universities, an NHS trust and the Medical Research Council's Clinical Trials Unit. The DoH announced plans to create a network of academic medical centres (AMCs) and the National Institute for Health Research (NIHR) last July.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.